Cargando…

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maharaj, Dipnarine, Srinivasan, Gayathri, Abreu, Maria M., Ko, Meng-Wei, Jewett, Anahid, Gouvea, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822209/ https://www.ncbi.nlm.nih.gov/pubmed/33375215 http://dx.doi.org/10.3390/cells10010010

Ejemplares similares

Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome
por: Maharaj, Dipnarine, et al.
Publicado: (2021)

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2018)

Erratum: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2017)

Correction: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
por: Burns, A, et al.
Publicado: (2019)

Molecular remission using low-dose immunotherapy for relapsed refractory Philadelphia chromosome-positive precursor B-cell acute lymphoblastic leukemia post-allogeneic stem cell transplant
por: Maharaj, Dipnarine, et al.
Publicado: (2019)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

High CXCR3 on Leukemic Cells Distinguishes IgHV(mut) from IgHV(unmut) in Chronic Lymphocytic Leukemia: Evidence from CD5(high) and CD5(low) Clones
por: Manukyan, Gayane, et al.
Publicado: (2020)

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
por: Rigoni, Micol, et al.
Publicado: (2015)

Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia
por: Eagle, Gina L., et al.
Publicado: (2015)

Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay
por: Mimmi, Selena, et al.
Publicado: (2022)

Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL
por: Bryant, Dean, et al.
Publicado: (2023)

Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors
por: Maharaj, Dipnarine, et al.
Publicado: (2017)

Vom Unmut zum Zorn
por: Ruhaltinger, Josef
Publicado: (2023)

Breiter Unmut über CERN-Ausstieg
Publicado: (2009)

Unmute the Organization Through Serious Play
por: Heldal, Frode, et al.
Publicado: (2021)

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
por: Hussmann, Dianna, et al.
Publicado: (2021)

Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency
por: Pal Singh, Simar, et al.
Publicado: (2018)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
por: Guo, Ailin, et al.
Publicado: (2015)

Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia
por: Rout, Emily D., et al.
Publicado: (2018)

Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia
por: Tschumper, Renee C., et al.
Publicado: (2019)

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
por: Kaufman, Matthew, et al.
Publicado: (2022)

HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia
por: Guo, Chao, et al.
Publicado: (2021)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo
por: Sarma, Supria, et al.
Publicado: (1999)

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
por: Qin, Shu-Chao, et al.
Publicado: (2017)

98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia
por: Shi, Ke, et al.
Publicado: (2019)

JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
por: Gangat, Naseema, et al.
Publicado: (2021)

Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development
por: Majc, Bernarda, et al.
Publicado: (2021)

ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor
por: Kaur, Kawaljit, et al.
Publicado: (2021)

Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia
por: Henriques, Ana, et al.
Publicado: (2013)

The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia
por: Yuan, Chaohui, et al.
Publicado: (2017)

Celebrating 20 Years of IGHV Mutation Analysis in CLL
por: Chiorazzi, Nicholas, et al.
Publicado: (2020)

New markers for murine memory B cells that define mutated and unmutated subsets
por: Anderson, Shannon M., et al.
Publicado: (2007)

Differential Requirement for Protein Synthesis in Presynaptic Unmuting and Muting in Hippocampal Glutamate Terminals
por: Crawford, Devon C., et al.
Publicado: (2012)

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
por: Bagnara, Davide, et al.
Publicado: (2021)

Increase in "Null" cells in acute lymphocytic leukaemia in remission on long-term immunotherapy.
por: Joseph, R. R., et al.
Publicado: (1976)

Cannot write session to /tmp/vufind_sessions/sess_kr4cf6hd2td5kmtbo1uja4rjf2